The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science

Area of Science:

• Biopharmaceutical industry
• Drug development
• Regulatory science

Background:

• Historically, the pharmaceutical industry has prioritized competition over collaboration.
• Other industries, like computer chip manufacturing and television development, have benefited from precompetitive collaborations on standards and applied science.
• This competitive landscape often hindered broad advancements and public benefit.

Purpose of the Study:

• To highlight the historical lack of precompetitive collaboration in the pharmaceutical industry.
• To identify the catalyst for change in pharmaceutical data sharing and collaboration.
• To underscore the potential benefits of collaborative efforts in drug development.

Main Methods:

• Comparative analysis of industry collaboration models.
• Review of historical pharmaceutical industry practices.
• Examination of the impact of the US Food and Drug Administration (FDA) Critical Path Initiative.

Main Results:

• Precompetitive collaborations are common and successful in sectors like technology and media.
• The pharmaceutical industry demonstrated limited willingness to share data and knowledge.
• The FDA's Critical Path Initiative (launched in 2004) marked a turning point, encouraging greater collaboration.

Conclusions:

• Industry-wide collaborations, particularly in precompetitive areas, can accelerate scientific and technological advancement.
• The pharmaceutical sector's shift towards collaboration, spurred by regulatory initiatives, has the potential to benefit all stakeholders and the public.
• Encouraging precompetitive research and data sharing is crucial for addressing complex challenges in drug development.